Craig J Hoesley1, Beatrice A Chen2,3, Peter L Anderson4, Charlene S Dezzutti2,3, Julie Strizki5, Carol Sprinkle2, Faye Heard1, Jose Bauermeister6, Wayne Hall3, Cindy Jacobson3, Jennifer Berthiaume7, Ashley Mayo8, Holly Gundacker7, Nicola Richardson-Harman9, Jeanna Piper10. 1. University of Alabama at Birmingham. 2. School of Medicine, University of Pittsburgh, Pennsylvania. 3. Magee-Womens Research Institute, Pittsburgh, Pennsylvania. 4. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora. 5. Merck & Co. Inc., Kenilworth, New Jersey. 6. University of Pennsylvania, Philadelphia. 7. Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention, Seattle, Washington. 8. FHI360, Durham, North Carolina. 9. Alpha StatConsult LLC, Damascus. 10. National Institutes of Health, Division of AIDS, Bethesda, Maryland.
Abstract
BACKGROUND:Vaginal rings (VR) containing antiretroviral (ARV) drugs can be utilized for prevention of human immunodeficiency virus (HIV) with potential for improved adherence compared to daily pills. Combination ARV VRs could improve efficacy. METHODS: MTN-027, a single-blind, randomized, placebo-controlled trial in 48 women, evaluated VRs containing MK-2048 (30 mg) andvicriviroc (VCV, 182 mg), alone or in combination, and placebo used continuously for 28 days. Safety was assessed by recording adverse events. Drug concentrations were quantified in plasma, vaginal fluid, cervical tissue, and rectal fluid. Cervical tissue was utilized for ex vivo HIV inhibition analysis. RESULTS: There was no difference in related genitourinary adverse events between treatment arms compared to placebo. VCV and MK-2048 released from single or combination VRs both achieved peak concentrations in vaginal fluids, which were substantially higher compared to plasma (200× for VCV, 30× for MK-2048) and rectal fluid. In an ex vivo challenge assay, the antiviral activity of VCV and/or MK-2048 was not correlated with tissue-associated drug concentrations. Most women (77%) were fully adherent to 28 days of continuous VR use and found the VR acceptable. CONCLUSIONS:VCV and/or MK-2048 containing VRs were safe and acceptable. Both VCV and MK-2048 were quantifiable in all matrixes tested with peak compartmental drug concentrations similar for single and combination drug VRs. Tissue-associated VCV and/or MK-2048 did not correlate with inhibition of HIV infection. These data highlight the need to assess adequacy of drug dosing in the VR and measuring genital tissue drug concentrations to develop more precise concentration-response relationships.
RCT Entities:
BACKGROUND: Vaginal rings (VR) containing antiretroviral (ARV) drugs can be utilized for prevention of human immunodeficiency virus (HIV) with potential for improved adherence compared to daily pills. Combination ARV VRs could improve efficacy. METHODS:MTN-027, a single-blind, randomized, placebo-controlled trial in 48 women, evaluated VRs containing MK-2048 (30 mg) and vicriviroc (VCV, 182 mg), alone or in combination, and placebo used continuously for 28 days. Safety was assessed by recording adverse events. Drug concentrations were quantified in plasma, vaginal fluid, cervical tissue, and rectal fluid. Cervical tissue was utilized for ex vivo HIV inhibition analysis. RESULTS: There was no difference in related genitourinary adverse events between treatment arms compared to placebo. VCV and MK-2048 released from single or combination VRs both achieved peak concentrations in vaginal fluids, which were substantially higher compared to plasma (200× for VCV, 30× for MK-2048) and rectal fluid. In an ex vivo challenge assay, the antiviral activity of VCV and/or MK-2048 was not correlated with tissue-associated drug concentrations. Most women (77%) were fully adherent to 28 days of continuous VR use and found the VR acceptable. CONCLUSIONS:VCV and/or MK-2048 containing VRs were safe and acceptable. Both VCV and MK-2048 were quantifiable in all matrixes tested with peak compartmental drug concentrations similar for single and combination drug VRs. Tissue-associated VCV and/or MK-2048 did not correlate with inhibition of HIV infection. These data highlight the need to assess adequacy of drug dosing in the VR and measuring genital tissue drug concentrations to develop more precise concentration-response relationships.
Authors: Jared M Baeten; Thesla Palanee-Phillips; Elizabeth R Brown; Katie Schwartz; Lydia E Soto-Torres; Vaneshree Govender; Nyaradzo M Mgodi; Flavia Matovu Kiweewa; Gonasagrie Nair; Felix Mhlanga; Samantha Siva; Linda-Gail Bekker; Nitesha Jeenarain; Zakir Gaffoor; Francis Martinson; Bonus Makanani; Arendevi Pather; Logashvari Naidoo; Marla Husnik; Barbra A Richardson; Urvi M Parikh; John W Mellors; Mark A Marzinke; Craig W Hendrix; Ariane van der Straten; Gita Ramjee; Zvavahera M Chirenje; Clemensia Nakabiito; Taha E Taha; Judith Jones; Ashley Mayo; Rachel Scheckter; Jennifer Berthiaume; Edward Livant; Cindy Jacobson; Patrick Ndase; Rhonda White; Karen Patterson; Donna Germuga; Beth Galaska; Katherine Bunge; Devika Singh; Daniel W Szydlo; Elizabeth T Montgomery; Barbara S Mensch; Kristine Torjesen; Cynthia I Grossman; Nahida Chakhtoura; Annalene Nel; Zeda Rosenberg; Ian McGowan; Sharon Hillier Journal: N Engl J Med Date: 2016-02-22 Impact factor: 91.245
Authors: Opass Putcharoen; Sun Hee Lee; Timothy J Henrich; Zixin Hu; Jakapat Vanichanan; Eoin Coakley; Wayne Greaves; Roy M Gulick; Daniel R Kuritzkes; Athe M N Tsibris Journal: J Virol Date: 2011-11-16 Impact factor: 5.103
Authors: Mitchell D Creinin; Leslie A Meyn; Lynn Borgatta; Kurt Barnhart; Jeff Jensen; Anne E Burke; Carolyn Westhoff; Melissa Gilliam; Caryn Dutton; Susan A Ballagh Journal: Obstet Gynecol Date: 2008-02 Impact factor: 7.661
Authors: Keith W Crawford; Chonghua Li; Anther Keung; Zhaohui Su; Michael D Hughes; Wayne Greaves; Daniel Kuritzkes; Roy Gulick; Charles Flexner Journal: J Acquir Immune Defic Syndr Date: 2010-04 Impact factor: 3.731
Authors: Annalene Nel; Linda-Gail Bekker; Elizabeth Bukusi; Elizabeth Hellstrӧm; Philip Kotze; Cheryl Louw; Francis Martinson; Gileard Masenga; Elizabeth Montgomery; Nelisiwe Ndaba; Ariane van der Straten; Neliëtte van Niekerk; Cynthia Woodsong Journal: PLoS One Date: 2016-03-10 Impact factor: 3.240
Authors: José A Bauermeister; Jesse M Golinkoff; Alex Carballo-Diéguez; Rebecca Giguere; Daniela López; Craig J Hoesley; Beatrice A Chen; Peter Anderson; Charlene S Dezzutti; Julie Strizki; Carol Sprinkle; Faye Heard; Wayne Hall; Cindy Jacobson; Jennifer Berthiaume; Ashley Mayo; Barbra A Richardson; Jeanna Piper Journal: AIDS Behav Date: 2020-02
Authors: Dvora L Joseph Davey; Linda-Gail Bekker; Elizabeth A Bukusi; Benjamin H Chi; Sinead Delany-Moretlwe; Ameena Goga; Anne Drapkin Lyerly; Nyaradzo M Mgodi; Nelly Mugo; Landon Myer; Lisa M Noguchi; Lynda Stranix-Chibanda; Catherine Slack; Jillian Pintye Journal: Lancet HIV Date: 2022-01-25 Impact factor: 16.070
Authors: Louise Carson; Ruth Merkatz; Elena Martinelli; Peter Boyd; Bruce Variano; Teresa Sallent; Robert Karl Malcolm Journal: Pharmaceutics Date: 2021-05-19 Impact factor: 6.321